Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?Vise andre og tillknytning
2023 (engelsk)Inngår i: Travel Medicine and Infectious Disease, ISSN 1477-8939, E-ISSN 1873-0442, Vol. 54, artikkel-id 102598Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]
Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.
sted, utgiver, år, opplag, sider
Elsevier, 2023. Vol. 54, artikkel-id 102598
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-210208DOI: 10.1016/j.tmaid.2023.102598ISI: 001019325700001PubMedID: 37271201Scopus ID: 2-s2.0-85161309981OAI: oai:DiVA.org:umu-210208DiVA, id: diva2:1776376
2023-06-282023-06-282025-02-20bibliografisk kontrollert